Tenderwize
Retour à la recherche

Rituximab infusion concentrate rebate agreement

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Oct 30, 2026 · 63 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Rituximab - in der Darreichungsform Infusionslösungskonzentrat (ATC: L01FA01)

58/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

58 / 100

Complexité

42 / 100

Facteurs de risque

Structured data says electronic submission is not allowed, while the XML notice mentions that signed PDF contract docum...

Structured data gives the deadline as 2026-10-30T23:00:00Z, while the XML notice shows EndDate 2026-10-31+01:00 at 00:0...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive rebate agreements for pharmaceutical products containing Rituximab in infusion concentrate form.
  • Open-house access model with uniform contract terms and a uniform access procedure.
Afficher le résumé complet

This is an open-house style German supply notice for non-exclusive rebate agreements for Rituximab infusion concentrate (ATC L01FA01) with AOK Sachsen-Anhalt. The notice states that any eligible pharmaceutical company may join on the same terms; no individual negotiations or exclusivity apply. The contract can start from 2025-01-01 and ends on 2026-12-31 regardless of start date. The notice is not presented as a public contract award in the usual procurement sense, but the publication uses the TED notice format. Procurement documents are referenced, but no extracted procurement document text beyond the XML notice was provided.

Risques

Structured data says electronic submission is not allowed, while the XML notice mentions that signed PDF contract docum...

Structured data gives the deadline as 2026-10-30T23:00:00Z, while the XML notice shows EndDate 2026-10-31+01:00 at 00:0...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • No individual contract negotiations are conducted.

Administrative

  • Interested pharmaceutical companies must request the participation documents and the contract from the contact address.
  • The participation documents must be completed in full and signed.

Critères d'attribution

Lot 1

Other criterion: equal access / no exclusivity

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Rituximab infusion concentrate rebate agreement

Single lot for non-exclusive rebate agreements for medicinal products containing Rituximab in infusion concentrate form (ATC L01FA01). The open-house model means any company meeting the participation conditions may conclude a contract on identical terms. No exclusivity and no individual negotiations are stated. The earliest contract start is 2025-01-01 and the contract ends on 2026-12-31.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Critères d'attribution

Other criterion: equal access / no exclusivity

Date limite

Deadline Oct 30, 2026

Détails de la procédure

Date de publication
12 Nov 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
691749-2024

Documents (1)

Appels d'offres similaires